Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company with a strong focus on lung disease and oncology, and its news flow reflects that specialization. Company updates frequently cover performance of its lung diagnostics business, including revenue trends, test volumes, and reimbursement developments for its Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance.
Investors and clinicians following BDSX news can expect regular financial and operating results releases, where Biodesix reports revenue from Lung Diagnostics and Development Services, discusses gross margins, and comments on measures such as Adjusted EBITDA. These announcements often describe factors influencing growth, such as increased test adoption, payer coverage, and expansion into clinical settings like pulmonology and primary care.
Biodesix also issues news about its Development Services activities and partnerships with biopharmaceutical and life sciences companies. Recent items include an expanded agreement to develop and clinically validate Droplet Digital PCR high complexity assays on Bio-Rad platforms, as well as availability of an ultra-sensitive ESR1 assay for biopharma customers and clinical use in advanced breast cancer.
Another recurring theme in BDSX news is scientific and medical conference participation. The company highlights poster presentations, workshops, and corporate events at meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. These stories showcase new clinical utility data for Nodify Lung tests, health economic analyses of pulmonary nodule management, and research on molecular diagnostic technologies such as NGS, ddPCR, and mass spectrometry.
In addition, Biodesix reports on corporate and capital markets developments, including reverse stock split actions and Nasdaq listing compliance updates, as well as investor conference participation. For users tracking BDSX, this news page provides a centralized view of operational performance, scientific progress, collaborations, and key corporate milestones over time.
Biodesix reported a 102% increase in core lung diagnostic revenue to $9.2 million for Q3 2022 compared to Q3 2021. Total revenue reached $11.1 million, up 70% year-over-year, driven by strong adoption of Nodify tests. Medicare now covers all five core lung diagnostic tests, enhancing growth prospects. Despite a net loss of $13.7 million, a decrease in operating loss indicates improved financial health. Cash reserves stand at $15.2 million. The company expects to meet its revenue guidance of $37.5-$39.5 million for 2022, emphasizing growth in lung diagnostics.
Biodesix, a diagnostic solutions company focused on lung disease, will release its Q3 financial results on November 3, 2022. The results will be made public before the market opens, followed by a conference call at 8:00 a.m. ET for a business update and Q&A session. Biodesix offers five Medicare-covered tests using advanced AI for lung disease diagnostics, which aids in treatment decisions and risk assessments for malignancies.
Biodesix announced a Federal Supply Schedule contract with the Veterans Health Administration to provide its lung diagnostic portfolio. This includes tests such as Nodify XL2® and GeneStrat®. The U.S. Department of Veterans Affairs serves over 9 million veterans, and the partnership aims to improve lung cancer care for this population, which has a higher risk of the disease. The company emphasizes its commitment to advancing diagnostic solutions in lung disease, leveraging AI capabilities to enhance patient outcomes.
Biodesix (Nasdaq: BDSX) announced new findings from the Nodify XL2® proteomic test at the CHEST 2022 Annual Meeting, showcasing its effectiveness in evaluating the malignancy risk of pulmonary nodules. Data from the ORACLE study indicates the test performs equally well for nodules identified through lung cancer screenings and incidental findings. With the expansion of eligibility for lung cancer screening in the U.S., the test could help reduce unnecessary biopsies for benign nodules. The presentations highlight the role of blood-based testing in more accurate risk stratification.
Biodesix (BDSX) reported strong preliminary results for Q3 2022, with estimated total revenues between
Biodesix (NASDAQ: BDSX), a leader in data-driven diagnostic solutions for lung disease, announced CEO Scott Hutton will participate in two investor conferences. The Morgan Stanley 20th Annual Global Healthcare Conference is on September 13, 2022, featuring a fireside chat at 9:10 a.m. ET. The H.C. Wainwright 24th Annual Global Investment Conference runs from September 12-14, 2022. Biodesix specializes in non-invasive tests for lung diseases, leveraging advanced AI technology to provide rapid and accurate diagnostic solutions.
Summary not available.
Biodesix reported Q2 2022 financial results showing a 52% increase in core lung diagnostic revenue, totaling $7.3 million, compared to the same period in 2021. The overall revenue was $11.0 million, an 8% decline due to decreased COVID-19 testing. The company has received Medicare coverage for its Nodify CDT® test, enhancing long-term margins. Operating expenses rose 21% to $18.6 million, with a net loss of $15.8 million. Biodesix reaffirms its 2022 revenue outlook of $37.5 million to $39.5 million.
Biodesix, a prominent diagnostic solutions company specializing in lung diseases, announced that CEO Scott Hutton will present at the Canaccord Genuity 42nd Annual Growth Conference, scheduled for August 10, 2022, at 3:00 PM ET in Boston. The event will be available for live streaming on Biodesix's website. The company is known for its innovative diagnostic tests, including the Nodify Lung® nodule risk assessment and IQLung™ strategies for lung cancer, aiming to expedite treatment decisions. Biodesix also launched COVID-19 diagnostic tests, responding to the ongoing pandemic.
Biodesix, Inc. (BDSX) has announced promising results from a retrospective analysis of its VeriStrat proteomic test presented by Dr. Young Kwang Chae at the IASLC 2022 World Conference on Lung Cancer in Vienna. This analysis focused on patients with advanced-stage non-small cell lung cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICIs) and highlighted that the test effectively predicts Progression Free Survival (PFS) and Overall Survival (OS) in patients with low or negative PD-L1 expression.